GI Oncology Daily Digest

Squamous-cell carcinoma of the anal canal (SCAC) has no FDA-approved therapy once it progresses after first-line platinum-based chemotherapy, which is the unmet need this designation targets. The FDA granted Fast Track to pelareorep — an intravenously delivered oncolytic reovirus — combined with a checkpoint inhibitor for inoperable, locally recurrent, or metastatic SCAC after one or more prior lines. The designation rests on the GOBLET study cohort, in which the combination produced an objective response rate of roughly 30% versus an ~13.8% historical benchmark, a median duration of response of about 15.5 versus 9.5 months, and a 12-month overall survival rate of 82% versus 45.7% historically. This is the third gastrointestinal Fast Track for pelareorep, after KRAS-mutant metastatic colorectal cancer (February 2026) and pancreatic cancer (2022). Important caveats: these are small, single-arm data benchmarked against historical controls, and Fast Track is a development-acceleration designation — not an approval and not evidence of benefit on its own. It does open more frequent FDA interaction, rolling BLA review, and potential Priority Review eligibility, and the response and survival signals justify a properly controlled randomized trial in a disease with essentially no standard second-line option.

This systematic review and meta-analysis pools the two pivotal phase III trials that established checkpoint inhibition in first-line MSI-H/dMMR metastatic colorectal cancer — KEYNOTE-177 (pembrolizumab) and CheckMate-8HW (nivolumab with or without ipilimumab) — across more than 600 patients. First-line immunotherapy reduced the risk of progression by nearly 40% (pooled PFS hazard ratio 0.61, 95% CI 0.51–0.73) and the risk of death by roughly a quarter (pooled OS hazard ratio 0.77, 95% CI 0.63–0.94), with no statistical heterogeneity (I²=0%) in either analysis. The benefit held consistently across BRAF, KRAS, and NRAS mutational status and across primary tumor sidedness, and despite more immune-related adverse events the immunotherapy arms carried a lower overall rate of grade ≥3 toxicity than chemotherapy. Nothing here is mechanistically new — both trials were already practice-changing — but the value is a clean, heterogeneity-free quantitative synthesis reinforcing that a patient with MSI-H/dMMR metastatic colorectal cancer should not receive chemotherapy as first-line therapy. The main limitation is pooling two structurally different regimens, but the message for practice is unambiguous: identify mismatch-repair status up front, every time.